Table 3.
Metabolic and hepatic parameters of the study population.
| Features | NLP | OSA | p-value |
|---|---|---|---|
| Frequency, n (%) | 43 (21.9) | 153 (78.1) | NA |
| Body mass index ≥ 30, n (%) | 13 (30.2) | 68 (44.4) | 0.095 |
| HOMA-IR score ≥ 3, n (%) | 14 (32.6) | 93 (60.8) | 0.001 |
| Type 2 diabetes mellitus, n (%) | 4 (9.3) | 25 (16.3) | 0.334 |
| Dyslipidemia, n (%) | 10 (23.3) | 74 (48.4) | 0.003 |
| Metabolic syndrome, n (%) | 4 (9.3) | 33 (21.6) | 0.080 |
| Hepatic steatosis | |||
| by Fatty Liver Index ≥ 60, n (%) | 15 (34.9) | 95 (62.1) | 0.001 |
| by Hepatic Steatosis Index ≥ 36, n (%) | 21 (48.8) | 104 (68) | 0.021 |
| NASH by OWLiver test, n (%) | 12 (27.9) | 77 (50.3) | 0.009 |
| Low risk of advanced fibrosis | |||
| FIB-4 <1.3, n (%) | 24 (55.8) | 94 (61.4) | 0.416 |
| NFS < −1.455, n (%) | 21 (48.8) | 64 (41.8) | 0.413 |
| HFS <0.12, n (%) | 35 (81.4) | 121 (79.1) | 0.833 |
| High risk of advanced fibrosis | |||
| FIB-4 > 3.25, n (%) | 0 (0) | 2 (1.3) | 1.000 |
| NFS > 0.675, n (%) | 1 (2.3) | 10 (6.5) | 0.461 |
| HFS ≥ 0.47, n (%) | 1 (2.3) | 4 (2.6) | 1.000 |
Data are shown as mean ± SD or as number of cases (%). NLP, subjects with normal lung parameters; OSA, obstructive sleep apnea; NA, not applicable; HOMA-IR, homeostatic model assessment-insulin resistance; NFS, NAFLD fibrosis score; HFS, Hepamet fibrosis score. Bold values are the statistically significant.